



**THERMOGENESIS' CRYOSEAL® "AUTOLOGOUS" FIBRIN SEALANT
JAPANESE CLINICAL TRIAL RESULTS ACCEPTED
FOR POSTER PRESENTATION AT OCTOBER 2005 AABB MEETING**

*Abstract of autologous fibrin sealant clinical results also to be published in
The September 2005 Transfusion medical journal*

RANCHO CORDOVA, California (August 9, 2005) – ThermoGenesis Corp. (NASDAQ: KOOL) announced today that Dr. Masaru Shimizu, Professor of Kyorin University School of Medicine, and principal investigator for the pivotal clinical trial to test the ability of CryoSeal "autologous" fibrin sealant to arrest bleeding in cardiovascular, orthopedic, neurosurgery and esophageal surgery patients, will present their data at the American Association of Blood Banks conference in Seattle, WA in October. The 72-patient trial, conducted at six clinical sites, included 17–20 cases for each of the four surgical fields, and the efficacy rate for all specialty departments combined was 90.3% (65/72). The abstract concludes that CryoSeal "autologous" fibrin sealant "demonstrated high efficacy, safety and usefulness". Asahi Kasei Medical Co. Ltd., exclusive distributor of the CryoSeal System in Japan, filed a Pre-Market Approval (PMA) submission with this clinical data in March 2005. The fibrin sealant market in Japan is currently estimated at \$130 million/year.

Philip Coelho, CEO of ThermoGenesis commented, "This is a key milestone in the development of the CryoSeal FS System as a new safe alternative source of surgical sealant for Japan, the world's largest market for conventional fibrin sealants. We recently concluded our U.S. clinical trial enrollment this past June and plan to submit our U.S. PMA for approval by the end of this calendar year. Conventional fibrin sealants are produced from 'pooled collections' of thousands of units of purchased human blood plasma and bovine blood or lung tissue. Recent reports in Japanese medical journals have identified these 'pooled' products as the source of parvovirus B19 transmission to patients which is a cause of hemolytic anemia."

Regulatory Status

ThermoGenesis Corp. has received a right to affix the CE Mark to the CryoSeal FS System from its European Notified Body. In Japan, Asahi Kasei Medical, who is the Japanese distributor, has completed their PMA submission to the MHLW. A 150-patient, blinded multi-center Phase III clinical trial of CryoSeal FS System has completed enrollment in the United States and a PMA submission is being prepared.

About Asahi Kasei Medical Co., Ltd.

Asahi Kasei Medical Co., Ltd. is a world leader in research, development, production and sales of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products, plasma therapy products, and blood transfusion products for medical therapy all over the world.

About THERMOGENESIS CORP.

ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company's technology platforms lead the world in their ability to produce biological products from single units of blood. Umbilical cord blood banks are utilizing the Company's BioArchive® System as a critical enabling technology for cryogenic archiving of stem cells for transplant, while its CryoSeal FS System is used to prepare hemostatic and adhesive surgical sealants from the patient's blood in about an hour. ThermoGenesis Corp. has been a leading supplier of state-of-the-art Ultra-Rapid Blood Plasma Freezers and Thawers to hospitals and blood banks since 1992.

The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company's control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission.

More Information, Contact:

THERMOGENESIS CORP.

Philip Coelho: (916) 858-5100